Next Generation Clinical Proteomics to Target Human Health Challenges
EMSL Project ID
46000
Abstract
Changes in protein expression revealed by proteomics technologies will potentially revolutionize the global understanding of human diseases by characterizing both distinct disease states and disease progression. Despite enormous potential, proteomics technologies have yet to deliver the expected breakthroughs for clinical practice. Specifically, the ability to discover and validate clinically useful biomarkers of disease prognosis or therapeutic response has been limited by technical issues relating to sensitivity, dynamic range, and throughput. To address these demands, we have established a program that will implement a ''next generation'' proteomics platform that applies new technical advances initially for the discovery of candidate protein biomarkers present in patients either diagnosed with or at risk of liver fibrosis and disease. The development of a safer, less invasive alternative to the liver biopsy procedure will provide significant health benefits for the early detection, diagnosis, and intervention of chronic liver disease such as hepatitis C virus (HCV) infection. We anticipate that targeted subsets of candidate biomarkers for the diagnosis, staging, treatment, and monitoring of liver fibrosis will facilitate the development of noninvasive methods to assess liver fibrosis and disease progression. To accomplish the goals of this program, we have assembled a diverse group of investigators within the State of Washington who possess significant expertise in the fields of basic science, virology, biostatistics, clinical medicine, and advanced proteomics technologies. Integral to this program will be the extension of the new proteomics measurement platform to address problems in other diseases, and to make it commercially available for broad clinical use.
Project Details
Start Date
2011-11-18
End Date
2014-09-19
Status
Closed
Released Data Link
Team
Principal Investigator
Team Members